Author: Jeremy Chia

A handful of Software-as-a-Service (SaaS) companies that I have a vested interest in released their quarterly results in the past few weeks. 

Here’s a quick round up on their performance and some insights from management.

Zoom Video Communications (NASDAQ: ZM)

The video conferencing leader continued to report healthy growth. In the three months ended 31 July 2021, it saw 54% year-on-year revenue growth on top of the 355% growth it enjoyed in the corresponding quarter a year ago. On a sequential basis, Zoom reported 6.8% revenue growth.

Zoom’s free cash flow margin for the latest quarter was an excellent 44% and the company is now sitting on more than US$5 billion in net cash. Although management expects some churn in its SMB (small, medium businesses) online segment, Zoom still seems to be in a high growth phase as its net dollar expansion rate continues to be above 130%.

Zoom is also spending on innovation as it accelerates the app ecosystem on its Zoom App platform. Eric Yuan, Zoom’s founder-CEO, shared the following comment in the company’s latest earnings conference call:

“Our internal innovation engine is very strong and bolstered by our growing Zoom Apps developer ecosystem and acquisitions such as Kites that will strengthen our position in AI transcription and translation. As organizations and people reimagine work, communications, and collaborations, we are faced with a once-in-a-lifetime opportunity to drive this evolution on multiple fronts.”

In terms of outlook, Zoom expects revenue of between US$1.015 billion to US$1.02 billion in the upcoming quarter, which is roughly flat quarter-on-quarter as the company is facing some churn from its SME clients. But from my vantage point, Zoom is still well-positioned for the long-term.

Veeva Systems Inc (NYSE: VEEV)

For the quarter ended 31 July 2021, the healthcare software company reported a 29% increase in revenue from a year ago, and 7.3% sequential growth in subscription revenue. Veeva is now sitting on US$2.2 billion in cash and equivalents and continues to generate a growing stream of free cash flow.

During Veeva’s latest earnings conference call, its founder-CEO Peter Gassner said:

“Looking at the bigger picture in clinical, we are advancing our vision to move the industry to digital trials that are patient-centric and paperless. On the product side, we are growing our product team significantly to support further innovations. On the customer side, early adopters are progressing with Veeva eConsent and Veeva Site Connect, and momentum with Veeva SiteVault Free continues. We are learning a lot as we bring sponsors, clinical research sites, and patients together in the Veeva Clinical Network. It’s an exciting area, and digital trials have the potential to change the course of drug development worldwide.”

Okta Inc (NASDAQ: OKTA)

Identity management software provider Okta reported healthy topline growth even as it lapped tough comparisons from a year ago. During the reporting quarter (the three months ended 31 July 2021), Okta’s revenue grew 59% year-on-year due in part to the inclusion of Auth0, which was acquired in May. Excluding Auth0, Okta’s organic revenue growth was still a healthy 39% year-over-year and 10.7% sequentially.

The company’s overall trailing 12 month net retention rate stood at 124% – which is great – and Okta’s standalone current remaining performance obligation was up 43% year-over-year.

Okta is guiding for US$325 million to US$327 million in total revenue for the next quarter, which would represent growth of 50% year-on-year and 3.2% sequentially.

During Okta’s latest earnings conference call, co-founder and CEO Todd McKinnon shared his confidence on the company’s future growth:

“As the world continues to work through the ongoing pandemic, organizations have had to maintain fluid plans for returning to offices. Regardless of the time line, it’s clear that most organizations are adopting plans that include more remote access. Organizations also realize that their interactions with customers will continue to shift more online and need to accelerate their digital transformation business plans. These factors, combined with the ever-evolving security threat landscape, mean that the demand for Okta’s modern identity solutions has never been greater.”

MongoDB Inc (NASDAQ: MDB)

The leading noSQL database provider saw its share price rise sharply last week after posting another set of excellent results. 

Revenue for the reporting quarter (the three months ended 31 July 2021) was up 44% year-on-year and 9.4% sequentially. Impressively, MongoDB’s Atlas product, which is a database hosted on the cloud, grew by 83% from a year ago as companies are starting to embrace the fully-managed MongoDB database-as-a-service offering.

Management is forecasting the next quarter to have sequential growth of between 0.5% and 2.7%.

MongoDB’s CEO, Dev Ittycheria, ended the company’s latest earnings conference call by saying:

“I just want to leave you with a few comments. First, I think what we really want to reinforce is that we believe customers realize that if they want to move fast, MongoDB is the best way to do so; second, Atlas’ growth of 83% reinforces the point that customers want a multi-cloud platform that enables them to innovate quickly and outsource the undifferentiated heavy lifting of managing their data infrastructure; third, we continue investing and evolving our go-to-market strategy across field sales, inside sales and the self-serve channels to capture this large market opportunity; and last but not least, we continue to roll out significant innovation to improve our platform through both ease of use and expansion of capabilities to encourage more and more customers to use MongoDB.”

DocuSign Inc (NASDAQ: DOCU)

The e-signature specialist continued its excellent run. For the three months ended 31 July 2021, DocuSign reported a 52% increase in revenue year-on-year, building on the 47% growth experienced in the same period last year. DocuSign’s revenue also rose 9.2% on a sequential basis, and its net retention rate continued to be high at 124%.

The company is also enjoying improving operating leverage and saw a free cash flow margin of 32% in the reporting quarter. DocuSign’s management is guiding for between US$526 million and US$532 million in revenue for the upcoming quarter, good for a 3.3% sequential growth rate at the midpoint.

In his opening remarks during DocuSign’s latest earnings conference call, CEO Dan Springer highlighted how the company is becoming an integral part of the tech stack in many companies’ adoption of digital workflows. He mentioned some examples in his opening remarks to analysts:

“Many have also seen a better way of doing business from anywhere. And we believe that will become their new normal. One of our customers, Stacy Johansen, who is the President of Downeast Insurance, told us that when COVID hit and they had to close their physical doors, DocuSign saved them. In her words, and I quote, If it weren’t for the ability to get an electronic signature, we wouldn’t have written half of the new business we did last year.

Having succeeded beyond expectations by fully embracing digital tools, Downeast resolved to do business this way from here on. Another example is one of Canada’s largest automotive dealers. In response to COVID, the company adopted DocuSign eSignature and DocuSign payments to support remote sales and service. The program was so successful, it spawned a larger initiative to offer digital transactions across their entire dealer network.

As one company executive put it, “DocuSign has become part of facilitating a full breadth of remote experiences.” These are just a few examples of what we’re seeing again and again, being able to do business and operate from anywhere is what people now expect, plus it saves time, money and trees.”

---

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in the shares of Zoom, MongoDB, Veeva, Docusign and Okta. Holdings are subject to change at any time.

Having options is an often underappreciated but valuable competitive advantage. Nassim Taleb, the author of the book, Antifragile, wrote, “An option is what makes you antifragile”.

Antifragile companies can thrive in times of chaos. But what constitutes optionality?

Optionality can come in the form of having opportunities to easily open up new business ventures. Think Amazon.com (NASDAQ: AMZN).

In its early days, Amazon was a first-party online retailer. At that time, all of its revenue came from selling products it bought and resold. But once Amazon built a substantial-enough user base, it easily pivoted its business into a marketplace and started generating revenue by providing services to third-party sellers to run their e-commerce business on Amazon’s marketplace.

Having the initial large user base gave Amazon the option to easily pivot into a marketplace.  That’s optionality.

As an investor, I often think about the options that a company has. Here are some examples of companies that I believe have the luxury of optionality.

Netflix Inc (NASDAQ: NFLX)

The streaming giant has built up an enviable catalogue of well-loved original content such as Stranger Things, Black Mirror, and more.

I believe Netflix can leverage this valuable intellectual property to grow revenues through selling merchandise, creating games, and even theme parks. Although these ideas may seem farfetched now, I think the possible options are exciting. To unlock all of these possibilities, Netflix’s management will need good execution and careful planning.

Besides original content, Netflix also commands a wide audience. That’s a valuable asset to own. At the moment, Netflix is laser-focused on its core offering of providing a great streaming service to its loyal user base. However, Netflix can easily upsell feature upgrades to its userbase in the future. Netflix has already announced that games could be included in a Netflix subscription in the future. If the introduction of games is a success, Netflix can have tiered subscription plans based on whether a user is willing to pay a higher premium for more of Netflix’s gaming services.

Upstart Holdings Inc (NASDAQ: UPST)

This fintech provides AI-powered software tools to banks that can better predict default rates on loans. Currently, Upstart is focusing on its core product of unsecured personal loans. Although this itself is a multi-billion dollar market (around US$84 billion), the bigger prize is in auto loans and home mortgages. Upstart’s AI tool could be leveraged to help banks make smarter loan decisions for both these markets.

With its purchase of Prodigy, a cloud-based automotive retail software provider, Upstart is already looking to grow into the auto loans market. The auto loans market is seven times the size of the unsecured personal loans market while the home mortgage market is multiple times larger than auto loans.

It is still early days for Upstart, but its pie could potentially grow much bigger if it is able to enter these new markets successfully.

Square Inc (NYSE: SQ)

Square started off by providing aspiring shopkeepers (the company calls them sellers) with a simple device that they can use to accept credit card payments. These square-shaped devices were much cheaper and easier to install than traditional card readers. 

After winning over users, Square leveraged on its seller base to upsell other software tools and to even provide loans to these sellers. 

But Square truly hit the gold mine when it released Cash App. This is a consumer-focused app for people to store money, transfer money to friends, and even directly deposit their wages into.

With a growing user base, Square has so many options to further monetiseCash App. Besides what has already been mentioned, Cash App also currently offers services such as investing, bitcoin trading, and debit cards. In the future, Square could roll out other services such as insurance, and buy now, pay later (BNPL). On BNPL, Square recently announced that it would be acquiring the Australia-based BNPL provider, Afterpay. The ability to roll out new features in Cash App is a valuable option that Square can easily take advantage of.

Coupang Inc (NYSE: CPNG)

South Korea’s e-commerce giant has already taken advantage of its gigantic logistics footprint in the country. From a 1st-party e-commerce player, Coupang now also acts as a third-party marketplace and delivers food and groceries.

There are many ways to grow its business, simply by offering new services to its third-party sellers to increase take rates, or to roll out new product offerings to its loyal consumer base by leveraging its logistics network.

With Coupang’s sprawling logistics infrastructure in South Korea in place, the options are abounding. But, Coupang is also careful in its spending. CEO Bom Kim said during the company’s recent 2021 second-quarter earnings conference call:

“We start with small bets, then test rigorously and invest more capital over time, but only into the opportunities we feel strongest about… …There are many other early-stage initiatives in the portfolio and I expect that we will not continue all of them. Only the investments whose underlying metrics show strong potential for meaningful cash flows in the future will earn their way to more significant investment.”

The bottom line

Optionality is a great trait to have as a company. It means that the company can easily build new revenue streams, create a more diverse business, and become a more resilient company. Thinking about the options that a company has gives me a better idea of how a company can transform in the future and what possibilities lie ahead.

---

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in the shares of Amazon.com Inc, Netflix, Upstart, Square and Coupang. Holdings are subject to change at any time.

How much of our portfolio should we invest in a high conviction stock?

This is an age-old question for any investor. In this article, I touch on two concepts – the absorbing barrier and Kelly criterion – and see how we can use them to structure the way we think about position sizing in investing.

Absorbing barrier

Imagine playing a game of Texas Hold’em poker and being dealt the best starting hand of the game – a pair of aces. This hand has an approximately 80% chance of winning against any other starting-hand combination.

What would be the ideal bet to make here? In theory, the bigger your bet, the bigger your expected return is on the investment because the odds of winning are tilted heavily in your favour. But does this mean we should bet all our savings on this hand? Probably not.

This is where the idea of the absorbing barrier becomes relevant. Nassim Taleb, author of a number of books, including Fooled by Randomness, explains,

“[A]bsorbing barrier is a point that you reach beyond which you can’t continue. You stop. So, for example, if you die, that’s an absorbing barrier. So, most people don’t realise, as Warren Buffett keeps saying, he says in order to make money, you must first survive. It’s not an option. It’s a condition. So once, you hit that point, you are done. You are finished. And that applies in the financial world of course to what we call ruin, financial ruin.”

The idea is that even if you have a big edge in a game, bet sizing matters. If you keep betting 100% of your net worth on a game of poker, even if you start off as an 80% favourite to win, in the long run, it will eventually result in financial ruin. This applies to any financial decision, even if the probability of the tail risk is extremely low.

In his Fat Tails Statistical Project, Taleb wrote,

“Every risk-taker who survived understands this. Warren Buffett understands this. Goldman Sachs understands this. They do not want small risks, they want zero risk because that is the difference between the firm surviving and not surviving over twenty, thirty, one hundred years.”

Kelly criterion

This brings us to the next topic, the Kelly criterion. The Kelly criterion is named after researcher J. L. Kelly who described a gambling formula for bet sizing that leads to the highest possible wealth compared to any other strategy if you have a slight edge in the game.

According to the Kelly criterion, the optimal size of an even-money bet is calculated by multiplying the percentage chance of winning by two and subtracting 100%. For a game that you have an 80% chance of winning, the optimal bet sizing is 60% of your available funds (80% x 2 – 100% = 60%). So if you lose your first bet, your next bet should be smaller, and vice versa.

By making the bet sizing a percentage of your available funds, the chances of complete financial ruin drop to zero as you will never bet all your available funds on a single bet.

However, as you may have guessed, in casinos and in gambling in general, you will probably never find a situation where you are a consistent favourite to win in an even-money bet. This is because casinos only offer games where the house has an advantage over the players.

Investment risk management

This is not the case in investing. Great stock pickers, with a proven approach, have higher odds of making winning bets by picking the right stocks to invest in.

Warren Buffett, for example, has been one of the investment greats of the past seven decades by consistently finding stock market winners to invest in. But even great stock pickers may not have a 100% track record. Despite his investing prowess, Buffett has admitted numerous investing mistakes, some of which has caused him or his firm to lose money.

And yet, Buffett is far from financial ruin. This is because of the position sizing for each of his investments and the diversification of his portfolio across a range of “bets”.

Real-life practicality

Calculating the ideal bet sizing using Kelly’s criterion may not be practical in real life investing, due to our inability to accurately calculate win rates and the fact that no investment is completely identical.

However, understanding the fundamentals behind absorbing barriers and the Kelly criterion can, at the very least, give us a framework to think about how to size our investments to reduce the risk of financial ruin over the long run. 

Portfolio positioning is a complicated topic and absorbing barriers and Kelly’s criterion are just some of the topics to consider. For more thoughts on portfolio sizing, you can read some of our other articles here and here.

---

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently do not have a vested interest in any shares mentioned. Holdings are subject to change at any time.

Data as of 25 June 2021

The SPAC (Special Purpose Acquisition Company) craze has well and truly hit the market. 

From making up just a fraction of all funds raised through IPOs in the USA in the past, SPACs have grown to become the bulk of IPOs in the first quarter of 2021. During the period, SPACs’ fundraising made up 69% of all IPO proceeds raised, up from around 20% in 2020.

The recent booming interest in SPACs raises a question: Do SPACs really make good investments? In this article, I run through some of the pros and cons of investing in SPACs, who are the winners and losers in this space, and why I’m avoiding any SPACs pre-merger.

Why are SPAC IPOs so popular?

SPACs are entities that are formed with the intention of merging with another existing company. SPAC investors will then become shareholders of the new combined entity.

When SPACs raise money at an IPO, investors are simply providing the “shell” company with the capital to acquire another business. Before acquiring a company, SPACs have no commercial operations and are therefore sometimes referred to as “blank check companies”. 

Part of the popularity of SPACs is their potential growth. If a SPAC is able to acquire a good company at a good valuation, investors could reap the long-term gains from the combined entity.

Some SPACs may be in a position to acquire great companies due to the SPAC sponsor. SPACs that are sponsored by big-name investors or expert investment managers have the connections and expertise to acquire an early-stage company that has the potential to grow much bigger.

SPACs also provide downside protection as SPAC shareholders have the right to redeem their shares and be repaid from the trust account should they not like the deal. If they choose to redeem their shares, SPAC shareholders can get back cash based on the IPO price per share plus interest.

Investors who are lucky enough to invest at the IPO can also reap some returns once the SPAC starts trading as the share prices of SPACs tend to trade at a premium to their cash value due to the hope that the SPAC can put the money to good use. 

SPACs often throw in an additional incentive for investors to invest at its IPO, known as a “warrant”. Warrants give holders the right to buy more shares from the company at a specific price on a specified future date. These warrants can be traded separately and can be worth more if the SPAC shares rise. These free warrants are an additional kickback to being an IPO SPAC investor.

Fees, dilution, and misaligned incentives

Although SPACs may seem enticing on the surface, there are associated costs that may make them a poor investment for latecomers.

One of the big costs to investing in SPACs is the “sponsor promote,” which are free shares that are issued to a SPAC’s sponsors once a merger is finalised.

For example, in a US$500 million SPAC, IPO investors may fork out US$500 million and receive 50 million in shares with a net cash value of US$10 each. But once a merger is secured, the SPAC sponsor gets free shares that typically make up 20% of the number of shares sold in the SPAC’s IPO.

As such, in my example, the number of SPAC shares increases from 50 million to 60 million and the net cash of each share drops to US$8.33.  So essentially, shareholders paid US$10 (or more if they bought in after the IPO when the price has risen) for a share that now only holds US$8.33 in cash.

In addition, redemptions may reduce the cash per share of the SPAC. Remember I mentioned that SPAC shareholders have the right to redeem shares at the IPO price plus interest. But redemptions are not good for the remaining shareholders of the SPAC.

Redemptions reduce the amount of cash left in the SPAC disproportionately more than reducing the share count. For example, a SPAC that raises US$500 million in cash may end up with around US$490 million in cash after accounting for IPO underwriting fees. However, to fulfil redemption requests, the SPAC still needs to pay back $10 per share for each share redeemed when the cash per share was actually only US$9.80 per share. 

Research by Stanford law found that while the SPACs they studied issued shares for roughly $10 and value their shares at $10 when they merge, at the time of a merger, the median SPAC holds cash of only $6.67. This is due to dilution, underwriting fees, and share redemptions.

Throw in the warrants that IPO investors are given, and the potential total dilution could be far worse. Investors who didn’t buy in at the IPO and didn’t receive warrants are fighting an uphill task to make a profit.

I haven’t even mentioned another cohort of investors who get special treatment- the PIPE investors. PIPE stands for private investment in public equity and these PIPE investors are offered shares just before a SPAC-merger deal closes to make up for any cash shortfall for the deal. PIPE investors are usually offered shares at IPO prices, which are lower than what the shares usually trade at.  Although not exactly dilutive, PIPE investors get much better deals than retail investors who bought in at market prices after the IPO.

Another risk is that SPAC deals may not always turn out so well. The study by Standford Law found that SPAC shares tend to drop by one-third of their value or more within a year following a merger. 

Some of the reasons why SPAC acquisitions may turn out poorly is due to misaligned incentives and the time scale involved. SPACs usually have a two-year time period to make an acquisition. This puts pressure on the sponsor to find a deal. To avoid closing the SPAC without finalising a merger, the sponsor may rush to complete a deal even if it may not be best for shareholders. These poor business acquisitions and heavy dilution may result in poor long-term stock performance for SPACs.

Winners and losers in SPACs

The odds of long-term success for SPAC shareholders are clearly stacked against them. The heavy dilution from “promote” shares given to the sponsor, the high fees involved, and the dilution from redemptions, put long-term shareholders on the back foot.

But not everyone is a loser.

The biggest winners in the deal are usually the sponsors. The sponsors are given promote shares even when they put up relatively little capital. Even if the share price falls, sponsors are able to make healthy profits as they received their shares at a very low cost.

Investors who invest during the IPO and sell before the merger may also reap substantial gains. As mentioned earlier. SPACs tend to trade at a premium to their net cash value before a merger is done due to the hope that a good deal can be struck.

IPO investors who bought in at cash value and sell in the stock market before a deal closes can make a healthy profit. They can also sell the warrants for extra profit on the side.

The losers are investors who invest after the IPO when the stock prices have risen to a large premium over the diluted net cash value. Unless the SPAC acquires an exceptional company at a really good price, latecomers to a SPAC are left with an uphill task to even make a profit.

Although there have been a few positive outcomes, the odds of long-term success, post-merger, are stacked against SPAC shareholders.

Conclusion

I get why the SPAC market is booming. Raising money at an IPO for SPACs is easy as investors believe they can make a quick buck even before a merger is confirmed. The warrants and redemption promise make it an even sweeter deal for IPO investors.  Sponsors are also enticed by the potential huge gains once they receive their promote shares which could be worth hundreds of millions of dollars.

However, for investors who are buying SPACs in the secondary market, the odds of success are much lower. Misaligned incentives and heavy dilution put long-term shareholders at a disadvantage.

The fact that SPAC shareholders rely on the sponsor to make a good acquisition creates even more uncertainty. Investors who want to buy SPACs on the open market should consider these factors when making any investment decision.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently do not have a vested interest in any shares mentioned. Holdings are subject to change at any time.

There are some exciting developments in the biotech space. This is not surprising, given the rising interest to invest in biotech. More money leads to more talent working on these projects and ultimately increases the odds of scientific breakthroughs.

With that said, here are some exciting biotech trends that could be game-changers in their respective fields.

Liquid biopsies

A biopsy is a procedure that involves the extraction of sample cells or tissue from a tumour to determine the extent of a disease. It is useful to determine the characteristics of the tumour, which helps doctors determine the next step of treatment.

Traditional biopsies are invasive procedures that may result in complications. Imagine taking a sample of a tumour in your liver. The process involves inserting a needle into your liver to extract the tumour sample. The risks to this procedure include bleeding, infection, accidental injury to nearby organs etc.

Enter liquid biopsies. A non-invasive procedure, liquid biopsies are simple blood tests that are able to detect characteristics of a tumour without needing to take a direct tissue sample. 

Tumours release a variety of biomolecules into the bloodstream that can be detected via a blood sample study. These biomolecules help doctors figure out what sort of treatment a patient needs without requiring an invasive traditional biopsy.

In addition, liquid biopsies could potentially become the first line of cancer-screening for healthy individuals. 

At the moment, the lack of good cancer screening has resulted in numerous cancer patients only being diagnosed late. As you may have heard, the earlier you detect cancer, the better your prognosis and the better the outcome of treatment. Due to the non-invasive nature of liquid biopsies, it could become an important first line of detection.

Companies such as Guardant Health (NASDAQ: GH) and the Illumina (NASDAQ: ILMN)-owned, GRAIL, are leading the way.

Guardant Health already has an FDA approved test called Guardant360 which can be used for tumour mutation profiling across all solid cancers. The test is gaining wider acceptance from oncologists, with more than 150,000 tests performed to date. Guardant Health is also actively testing liquid biopsies as a screening tool with a major study in place since 2019. If the trial is successful, the company will submit its test for FDA approval which could become a game-changer in cancer screening.

CRISPR gene editing

For some time now, scientists have realised that specific genes in our body may predispose us to diseases or may cause inherited diseases to pass from generation to generation.

Although they may have identified genes that are causing these diseases, scientists have not been able to alter the gene sequences in question to reverse or prevent the diseases from occurring. CRISPR gene editing may change this.

CRISPR, which is short for Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing method that scientists have identified to efficiently and precisely modify, delete, or replace parts of the human DNA.

Scientists aim to develop gene-based medicines based on CRISPR technology to remove disease-causing genes. This could potentially solve the problem of genetic diseases such as sickle cell anaemia, cystic fibrosis, haemophilia, and many more.

CRISPR Therapeutics AG (NASDAQ: CRSP) and Editas Medicine Inc (NASDAQ: EDIT) are two companies that are focused on the transformative potential of CRISPR gene-editing technology. 

CRISPR Therapeutics currently has two programs that are at the clinical trial stages. The first is a therapeutic program to treat inherited hemoglobinopathies, β-thalassemia and sickle cell disease. Both these diseases are significant global burdens with around 300,000 and 60,000 babies born with sickle cell disease and β-thalassemia, respectively, each year.

The second is CRISPR Therapeutics’ Immuno-Oncology program. Immuno-Oncology is the use of immune cells to seek and destroy cancer cells. CRISPR Therapeutics aims to use CRISP technology to generate off-the-shelf immune cells that can be more easily administered and produced than the current CAR-T therapies that require the patient’s own genes. 

Similarly, Editas Medicine has two programs that are in early-stage clinical trials. The first is for the treatment of Leber Congenital Amaurosis 10 (LCA10), which is a group of inherited retinal degenerative disorders that are the most common cause of inherited childhood blindness affecting 3 of every 100,000 children globally.

The other program in early-stage clinical trials is for the treatment of sickle cell disease. 

Both companies are also developing other solutions for numerous other diseases which are in much earlier stages of development.

Although CRISPR gene-editing technology is still in its infancy, the potential of the technology seems very promising.

Tumour treating fields

Another interesting development in oncology is the use of tumour treating fields. This involves the application of alternating electric fields to disorientate the positions of tumour cell proteins which in turn disrupt the cell division of tumour cells. 

Novocure Ltd (NASDAQ: NVCR) is a key player in this arena. I first wrote about Novocure a year ago. Since then, the stock price has climbed by more than 200%, perhaps due to good news regarding some of its ongoing clinical trials. 

Currently, Novocure’s tumour treating field solution is FDA-approved for recurrent and newly diagnosed glioblastoma and mesothelioma. 

It is also in late-stage clinical trials for brain metastasis, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and phase II clinical trials for liver and gastric cancer.

There has also been higher adoption of its commercialised products over the year with the company reporting a 12% increase in active patients and a 32% increase in net revenues in the first quarter of 2021.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. Ser Jing and I currently have a vested interest in the shares of Illumina Inc. Holdings are subject to change at any time.

Ser Jing and I manage an investment fund that invests in a number of software-as-a-service (SaaS) companies.

Over the past few weeks, a handful of them reported their quarterly earnings results. Here’s a quick summary of how they performed and highlights from their respective analyst briefings.

DocuSign Inc (NASDAQ: DOCU)

The leader in e-signatures posted a solid set of results for the quarter ended 30 April 2021. Revenue was up 58% year-on-year to US$469.1 million, billings grew 54% to US$527.4 million, the gross margin improved to 78%, and free cash flow more than tripled to US$123.0 million. DocuSign’s free cash flow margin (free cash flow as a percentage of revenue) is also now a healthy 26%.
To me, the most impressive part was that the company’s revenue grew 9% sequentially. This is a solid achievement considering that DocuSign’s last three quarters prior to the latest reporting quarter have been positively impacted by COVID-19. 

In the quarter ended 30 April 2021, DocuSign added 96,000 and 11,000 net new total customers and enterprise and commercial customers, respectively. These translate to respective sequential growth of 10.7% and 8.8%, and should set DocuSign up well for the rest of the year.

DocuSign’s CEO Dan Springer said the following in the company’s latest earnings conference call: 

“Since the start of the pandemic, DocuSign has helped accelerate access to healthcare, government, education, small business lending and many other services around the world. What began as an urgent need has now transformed into a strategic priority. And as a result, DocuSign has become an indispensable part of many organization’s business processes.

Put another way, once businesses usually transform their agreement processes, they simply don’t go back. We believe this trend will only accelerate as that anywhere economy continues to emerge.”

MongoDB Inc (NASDAQ: MDB)

The leading NoSQL database provider started its fiscal year 2022 with a bang.

For the first quarter of fiscal year 2022, revenue climbed 39% year-on-year to US$181.6 million and the company turned free cash flow positive this quarter (US$9.6 million) from a negative figure (-US$7.4 million) a year ago.

MongoDB also recorded sequential revenue growth of 5.8%, which should set it up nicely for the coming quarters as the company laps last year’s strong results. 

During MongoDB’s earnings conference call for the first quarter of fiscal year 2022, CEO Dev Ittycheria said, 

“As we look to the future, there are a number of reasons why we are bullish about our long-term prospects. 

First, we are seeing increased adoption, enterprise adoption of Atlas. In the first quarter, approximately two-thirds of new business won by our field sales team was Atlas, more than double the percentage from 2 years ago. Not only are our customers choosing more of Atlas, they’re building or moving mission-critical workloads onto Atlas, which is the biggest driver of growth of our more than 1000 six-figure customers.

Second, cloud partners are recognizing the value that MongoDB and Atlas bring to their own businesses. Using Q1 as an example, we had a record co-sell quarter with AWS, GCP and Alibaba. We are seeing increasing opportunities to expand ways we partner with cloud providers through both technical integrations as well as go-to-market initiatives to enable more customers around the world to derive the benefits of using MongoDB.

Finally, our C level customer conversations indicate that our application data platform strategy is clearly resonating in the marketplace. Customers increasingly tell us that they prefer to standardize on a general-purpose platform, rather than use a myriad of single function databases that add more cost and increase the complexity of running workloads in the cloud.”

Veeva Systems Inc (NYSE: VEEV)

Continuing the winning theme, Veeva, which provides a suite of cloud software solutions for the global life sciences industry, announced a good set of results for the quarter ended 30 April 2021. 

Revenue grew 29% from a year ago to US$433.6 million, operating income rose 47% to US$128.4 million and the company added 59 new customers to bring its customer account above 1,000. On a sequential basis, Veeva’s revenue grew 9.2%.

Veeva’s CEO Peter Gassner shared the following comments during the company’s latest earnings conference call: 

“Our level of partnership with the industry is noticeably increasing, and there are multiple reasons for this. With every quarter of customer success and reliable delivery, Veeva becomes a more trusted partner. Our expanding product footprint, with products such as CDMS, Safety, MyVeeva, and Data Cloud, also makes Veeva a more strategic partner. The move to a digital-first way of working is also making technology and data more strategic overall to our customers. And finally, our move to operating as a public benefit corporation is encouraging to our customers as they look to us for long-term partnership.”

Okta Inc (NASDAQ: OKTA)

Okta, the leading identity and account management company, reported a 37% year-on-year rise in revenue to US$251.0 million for the quarter ended 30 April 2021. The company’s current remaining performance obligation rose 45% year-on-year to US$899 million, setting it up nicely for the next 12 months. Okta’s free cash flow margin also improved to 21% from 16% in the same quarter a year ago.

Notably, Okta’s revenue grew by 7.3% sequentially, which shows that the company can still grow from its high base in the last fiscal year. Okta also added 650 net new customers in the quarter bringing its total to 10,650.

Okta’s CEO, Todd McKinnon, is bullish on the company’s prospects of becoming a primary cloud provider as it expands its capabilities and integrates with its recent acquisition of Auth0. He said the following in the company’s latest earnings conference call:

“Okta is well-positioned to become the standard for digital identity. The Okta and Auth0 platforms are made up of core technologies that are flexible, extensible, and incredibly customizable to make that spectrum possible. By building a platform that connects with everything and meets every identity use case, over time, we’ll push the technology ecosystem to be safer and create more value for everyone. Together, Okta and Auth0 create a powerful combination.

We’ve strengthened our position as the world’s leading independent identity cloud. We’ll create even more powerful network effects that will drive platform innovation, allowing us to better serve our customers with a broader range of use cases and audiences. And as a result, we’ll capture more of the massive and growing $80 billion identity market opportunity even faster. The world is still in the early stages of modernizing its identity infrastructure.

The secular trends I mentioned earlier that have been driving our business will continue to drive our business for years to come. With that as a backdrop, we’re establishing a new long-term financial target, which is a significant step-up from our prior FY ’24 framework. Given our market-leading position, unmatched technology portfolio, and the massive market opportunity, we’re confident that we can grow our revenue base to achieve $4 billion in FY ’26. With growth of at least 35% each year, along the way, we will continue to invest in driving product innovation and our go-to-market initiatives while targeting a free cash flow margin of 20% in FY ’26.”

Salesforce (NYSE: CRM)

One of the pioneers of SaaS business model, Salesforce had a strong start to fiscal 2022. Revenue was up 23% year-on-year to US$5.96 billion, current remaining performance obligation grew 23% to US$17.8 billion, while the weighted average diluted share count only increased 2.9%.

On a sequential basis, Salesforce’s revenue rose 2.4% which is decent as Salesforce has a seasonal sales cycle. The compant’s CEO Marc Benioff is as bullish as ever. During Salesforce’s latest earnings call, he commented: 

“Now, for fiscal 2022. I’m thrilled we are raising our revenue, our guide by $250 million to $26 billion. This is one of the largest raises we’ve really ever had. It represents 22% projected growth year-over-year. And we’re not just raising revenue. And again, thanks to Amy, we’re raising our operating margin to 18%. So that is incredible. And in a few years, we’re going to be doing $50 billion ($21.25 billion in 2020) and by the fiscal year 2026. So that is an incredible thing.”

He also touched on why he believes Slack will make a good addition to Salesforce. He said, 

“And this pending acquisition of Slack also. We’ve never been better positioned for the future. This is an all-digital, it’s an all work from anywhere world. It’s made our companies, Salesforce and Slack, more important to customers than ever. So bringing them together is so exciting. And once this merger is approved, we’re going to be able to build Slack and all of our products will all become Slack-first. It’s going to make our customers more productive.

We’re going to work with software companies on building incredible new capabilities like we’ve seen these amazing examples of what Slack can do. I’ll tell you we’re really excited about creating this number one enterprise applications company.”

Zoom Video Communications Inc (NASDAQ: ZM)

One of the biggest winners of the COVID-19 pandemic, Zoom continues to post excellent results.

It reported a 191% year-over-year increase in revenue to US$956.2 million in the quarter ended 30 April 2021. GAAP net income increased more than eight-fold to US$227.4 million and free cash flow increased by 80% to US$454.2 million. The free cash flow margin for the quarter was an industry-leading 48%.

On a sequential basis, Zoom’s revenue grew by 8.4%, allaying fears that customer-churn from the reopening of economies around the world would impact Zoom’s revenue growth.

Although Zoom’s growth is expected to slow from the incredible numbers seen in FY2021 (326% revenue growth), Zoom still expects total revenue in 2022 to be between US$3.975 billion and US$3.99 billion, compared to US$2.6 billion in FY2021. This translates to growth of 50% at the low end.

Zoom’s CEO, Eric Yuan, said in the company’s latest earnings call: 

“In a recent survey we conducted, 80% of U.S. respondents agreed that all interactions will continue to have a virtual element post-pandemic, and that figure was even higher in many of the other markets we surveyed. The hybrid model is here to stay, and Zoom Events will be an excellent solution for our customers who are looking to create and host company events with a versatile and powerful solution.”

Yuan also highlighted some big customer wins during the quarter, which demonstrates Zoom’s strong value proposition in the midst of heavy competition from the other tech giants that are trying to shoulder their way into the videoconferencing space.

Summary

It has, without doubt, been a great start of the year for the SaaS companies in our portfolio.

Although the amazing growth in 2020 is not expected to repeat, the above-mentioned companies continue to see strong secular tailwinds and are executing well.

Sequential growth from the last quarter also shows that these companies are continuing to grow and are experiencing minimal customer-churn despite the reopening of the economy.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. Ser Jing and I currently have a vested interest in the shares of Veeva, Zoom, Salesforce, MongoDB, Okta and Docusign. Holdings are subject to change at any time.